Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of MK-2060 IV Administration in Healthy Participants
NCT06582602Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2024
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-2060 in venous thrombosis (6 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants With An Adverse Event (AE) up to 134 days and Number of Participants Discontinuing the Study Due to an AE up to 134 days. Started Oct 2024; status: completed.
02
Drugs
MK-2060
03
Conditions
venous thrombosis
Beyond the preview
Go deeper on NCT06582602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06582602.